Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
了解更多
The Faces of Luminex: Kurt Hoffacker, Chemistry R&D
Developing immunoassay technology and platforms takes innovation and hard work on a number of fronts—hardware, software, reagents, and more. We count on Kurt Hoffacker, Director of Chemistry R&D, to ensure that reagent development goes smoothly, and ultimately leads to products that integrate well with the rest of the Luminex systems. He has been a key member of our chemistry team since 1999.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
March 13th
Luminex Provides Update on SARS-CoV-2 Validation Testing Efforts
March 4th
Luminex Provides Updates on Critical Efforts Related to Novel Coronavirus
AACR Annual Meeting
April 24-29
San Diego, CA
Clinical Virology Symposium (CVS)
May 3-6
West Palm Beach, FL
Immunology
May 8-12
Honolulu, HI
